Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Summary: Background Cutaneous reactions after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are poorly characterized. Objective To describe and classify cutaneous reactions after SARS-CoV-2 vaccination. Methods A nationwide Spanish cross-sectional study was conducted. We included patients with cutaneous reactions within 21 days of any dose of the approved vaccines at the time of the study. After a face-to-face visit with a dermatologist, information on cutaneous reactions was collected via an online professional survey and clinical photographs were sent by email. Investigators searched for consensus on clinical patterns and classification. Results From 16 February to 15 May 2021, we collected 405 reactions after vaccination with the BNT162b2 (Pfizer-BioNTech; 40·2%), mRNA-1273 (Moderna; 36·3%) and AZD1222 (AstraZeneca; 23·5%) vaccines. Mean patient age was 50·7 years and 80·2% were female. Cutaneous reactions were classified as injection site (‘COVID arm’, 32·1%), urticaria (14·6%), morbilliform (8·9%), papulovesicular (6·4%), pityriasis rosea-like (4·9%) and purpuric (4%) reactions. Varicella zoster and herpes simplex virus reactivations accounted for 13·8% of reactions. The COVID arm was almost exclusive to women (95·4%). The most reported reactions in each vaccine group were COVID arm (mRNA-1273, Moderna, 61·9%), varicella zoster virus reactivation (BNT162b2, Pfizer-BioNTech, 17·2%) and urticaria (AZD1222, AstraZeneca, 21·1%). Most reactions to the mRNA-1273 (Moderna) vaccine were described in women (90·5%). Eighty reactions (21%) were classified as severe/very severe and 81% required treatment. Conclusions Cutaneous reactions after SARS-CoV-2 vaccination are heterogeneous. Most are mild-to-moderate and self-limiting, although severe/very severe reactions are reported. Knowledge of these reactions during mass vaccination may help healthcare professionals and reassure patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
SARS-CoV-2 vaccines in development
Krammer, F. (2020) · Nature · doi:10.1038/s41586-020-2798-3 · Cited by 2,098
Pollán, M., Pérez-Gómez, B., Pastor-Barriuso, R., Oteo, J., Hernán, M. A., Pérez-Olmeda, M., Sanmartín, J. L., Fernández-García, A., Cruz, I., Fernández de Larrea, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31483-5 · Cited by 1,639
Zuberbier, T., Aberer, W., Asero, R., Abdul Latiff, A. H., Baker, D., Ballmer‐Weber, B., Bernstein, J. A., Bindslev‐Jensen, C., Brzoza, Z., Buense Bedrikow, R., et al. (2018) · Allergy · doi:10.1111/all.13397 · Cited by 1,445
Ramasamy, M. N., Minassian, A. M., Ewer, K. J., Flaxman, A. L., Folegatti, P. M., Owens, D. R., Voysey, M., Aley, P. K., Angus, B., Babbage, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32466-1 · Cited by 1,324
Galván Casas, C., Català, A., Carretero Hernández, G., Rodríguez‐Jiménez, P., Fernández‐Nieto, D., Rodríguez‐Villa Lario, A., Navarro Fernández, I., Ruiz‐Villaverde, R., Falkenhain‐López, D., Llamas Velasco, M., et al. (2020) · British Journal of Dermatology · doi:10.1111/bjd.19163 · Cited by 1,225
Self-citationInterim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
Sadoff, J., Le Gars, M., Shukarev, G., Heerwegh, D., Truyers, C., de Groot, A. M., Stoop, J., Tete, S., Van Damme, W., Leroux-Roels, I., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034201 · Cited by 1,208
The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance
Phelan, A. L., Katz, R., & Gostin, L. O. (2020) · JAMA · doi:10.1001/jama.2020.1097 · Cited by 1,207
The Xs and Y of immune responses to viral vaccines
Klein, S. L., Jedlicka, A., & Pekosz, A. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70049-9 · Cited by 815
McMahon, D. E., Amerson, E., Rosenbach, M., Lipoff, J. B., Moustafa, D., Tyagi, A., Desai, S. R., French, L. E., Lim, H. W., Thiers, B. H., et al. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.03.092 · Cited by 808
Shimabukuro, T. T., Cole, M., & Su, J. R. (2021) · JAMA · doi:10.1001/jama.2021.1967 · Cited by 475
Skin Manifestations Associated with COVID-19: Current Knowledge and Future Perspectives
Genovese, G., Moltrasio, C., Berti, E., & Marzano, A. V. (2021) · Dermatology · doi:10.1159/000512932 · Cited by 288
Johnson, R. W., Alvarez-Pasquin, M.-J., Bijl, M., Franco, E., Gaillat, J., Clara, J. G., Labetoulle, M., Michel, J.-P., Naldi, L., Sanmarti, L. S., et al. (2015) · Therapeutic Advances in Vaccines · doi:10.1177/2051013615599151 · Cited by 288
Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2
Blumenthal, K. G., Freeman, E. E., Saff, R. R., Robinson, L. B., Wolfson, A. R., Foreman, R. K., Hashimoto, D., Banerji, A., Li, L., Anvari, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2102131 · Cited by 269
Mortz, C. G., Andersen, K. E., Dellgren, C., Barington, T., & Bindslev‐Jensen, C. (2015) · Allergy · doi:10.1111/all.12619 · Cited by 267
Munavalli, G. G., Guthridge, R., Knutsen-Larson, S., Brodsky, A., Matthew, E. J., & Landau, M. (2021) · Archives of Dermatological Research · doi:10.1007/s00403-021-02190-6 · Cited by 165
Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine: A Case Series
Johnston, M. S., Galan, A., Watsky, K. L., & Little, A. J. (2021) · JAMA Dermatology · doi:10.1001/jamadermatol.2021.1214 · Cited by 129
Varicella-zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: Report of 5 cases
Rodríguez-Jiménez, P., Chicharro, P., Cabrera, L.-M., Seguí, M., Morales-Caballero, Á., Llamas-Velasco, M., & Sánchez-Pérez, J. (2021) · JAAD Case Reports · doi:10.1016/j.jdcr.2021.04.014 · Cited by 122
Self-citationThe prevalence and persistence of atopic dermatitis in urban United States children
McKenzie, C., & Silverberg, J. I. (2019) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2019.05.014 · Cited by 105
Fernández‐Nieto, D., Hammerle, J., Fernández-Escribano, M., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17250 · Cited by 84
Self-citationLichen planus arising after COVID‐19 vaccination
Hiltun, I., Aldecoa‐Otalora, J. S., Martínez‐de‐Espronceda, I., Garcés, A., Llanos, C., Vives, R., & Yanguas, J. I. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17221 · Cited by 82
Self-citationMunavalli, G. G., Knutsen-Larson, S., Lupo, M. P., & Geronemus, R. G. (2021) · JAAD Case Reports · doi:10.1016/j.jdcr.2021.02.018 · Cited by 80
Marzano, A. V., Genovese, G., Moltrasio, C., Gaspari, V., Vezzoli, P., Maione, V., Misciali, C., Sena, P., Patrizi, A., Offidani, A., et al. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.01.023 · Cited by 79
Does influenza vaccination induce bullous pemphigoid? A report of four cases
Downs, Lear, Bower, & Kennedy (1998) · British Journal of Dermatology · doi:10.1046/j.1365-2133.1998.02097.x · Cited by 54
Pityriasis rosea‐like eruptions following vaccination with BNT162b2 mRNA COVID‐19 Vaccine
Cyrenne, B. M., Al‐Mohammedi, F., DeKoven, J. G., & Alhusayen, R. O. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17342 · Cited by 48
Ferretti, F., Cannatelli, R., Benucci, M., Carmagnola, S., Clementi, E., Danelli, P., Dilillo, D., Fiorina, P., Galli, M., Gallieni, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.656362 · Cited by 39
Piccolo, V., Bassi, A., Argenziano, G., Mazzatenta, C., Cutrone, M., Neri, I., Grimalt, R., & Russo, T. P. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17320 · Cited by 33
Pityriasis rosea following CoronaVac COVID‐19 vaccination: a case report
Akdaş, E., İlter, N., Öğüt, B., & Erdem, Ö. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17316 · Cited by 31
Chilblain lesions after COVID‐19 mRNA vaccine
Pileri, A., Guglielmo, A., Raone, B., et al. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20060 · Cited by 23
COVID‐19 “second wave” and vaccines: the dermatologists’ perspective
Burlando, M., Russo, R. L., Cozzani, E., et al. (2021) · International Journal of Dermatology · doi:10.1111/ijd.15547 · Cited by 22
Metadata
- Authors
- Català, A., Muñoz-Santos, C., Galván-Casas, C., Roncero Riesco, M., Revilla Nebreda, D., Solá-Truyols, A., Giavedoni, P., Llamas-Velasco, M., González-Cruz, C., Cubiró, X., Ruíz-Villaverde, R., Gómez-Armayones, S., Gil Mateo, M. P., Pesqué, D., Marcantonio, O., Fernández-Nieto, D., Romaní, J., Iglesias Pena, N., Carnero Gonzalez, L., Tercedor-Sanchez, J., Carretero, G., Masat-Ticó, T., Rodríguez-Jiménez, P., Gimenez-Arnau, A. M., Utrera-Busquets, M., Vargas Laguna, E., Angulo Menéndez, A. G., San Juan Lasser, E., Iglesias-Sancho, M., Alonso Naranjo, L., Hiltun, I., Cutillas Marco, E., Polimon Olabarrieta, I., Marinero Escobedo, S., García-Navarro, X., Calderón Gutiérrez, M. J., Baeza-Hernández, G., Bou Camps, L., Toledo-Pastrana, T., & Guilabert, A.
- Venue
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-01-01
- Volume
- 186
- Issue
- 1
- Pages
- 142-152
- ISSN
- 0007-0963 (ISSN-L)
- 1365-2133
- OpenAlex
- W3179320009
- Cited by
- 240
- References
- 31
- FWCI
- 41.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.